A20, ABIN-1/2, and CARD11 mutations and their prognostic value in gastrointestinal diffuse large B-cell lymphoma

Gehong Dong, Estelle Chanudet, Naiyan Zeng, Alex Appert, Yun Wen Chen, Wing Yan Au, Rifat A. Hamoudi, A. James Watkins, Hongtao Ye, Hongxiang Liu, Zifen Gao, Shih Sung Chuang, Gopesh Srivastava, Ming Qing Du

Research output: Contribution to journalArticle

48 Citations (Scopus)

Abstract

Purpose: Diffuse large B-cell lymphoma (DLBCL) is a heterogeneous group of aggressive lymphomas with the activated B-cell-like subtype characterized by constitutive NF-kB activation. Activating mutations of CARD11 and inactivating mutations of A20 are frequent events in DLBCL. However, the full extent of genetic alterations in the NF-κB pathway regulators and their potential prognostic value in DLBCL remain to be investigated. We investigated the genetic abnormalities of CARD11, A20, and ABIN-1/2/3 (the A20 binding inhibitor of NF-κB) and their clinicopathologic correlation in gastrointestinal DLBCL. Experimental Design: The somatic mutation and copy number changes of CARD11, A20, and ABIN-1/ 2/3 were investigated in 71 gastrointestinal DLBCLs by PCR/sequencing, and interphase FISH/array comparative genomic hybridization, respectively. The mutations identified were functionally characterized by NF-κB reporter assays and immunoprecipitation experiments. Results: Recurrent somatic mutations were found in CARD11 (10%), A20 (17%), ABIN-1 (4%), and ABIN-2 (3%), but not in ABIN-3. In comparison with the wild-type, all CARD11 mutants were potent NF-κB activators in vitro. On the basis of the destructive nature of the observed mutations, and the findings by reporter assays and immunoprecipitation studies, most if not all of the somatic mutations that were seen in A20, ABIN-1, and ABIN-2 could impair their normal functions. Among these genetic abnormalities, A20 somatic mutation was significantly associated with both poor overall survival and event-free survival. Conclusions: We show further evidence of NF-kB pathway genetic abnormalities in DLBCL, which are potentially valuable in the prognosis and design of future therapeutic strategies.

Original languageEnglish
Pages (from-to)1440-1451
Number of pages12
JournalClinical Cancer Research
Volume17
Issue number6
DOIs
Publication statusPublished - Mar 15 2011

Fingerprint

Lymphoma, Large B-Cell, Diffuse
Mutation
NF-kappa B
Immunoprecipitation
Comparative Genomic Hybridization
Interphase
Disease-Free Survival
Lymphoma
B-Lymphocytes
Research Design
Polymerase Chain Reaction

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

A20, ABIN-1/2, and CARD11 mutations and their prognostic value in gastrointestinal diffuse large B-cell lymphoma. / Dong, Gehong; Chanudet, Estelle; Zeng, Naiyan; Appert, Alex; Chen, Yun Wen; Au, Wing Yan; Hamoudi, Rifat A.; Watkins, A. James; Ye, Hongtao; Liu, Hongxiang; Gao, Zifen; Chuang, Shih Sung; Srivastava, Gopesh; Du, Ming Qing.

In: Clinical Cancer Research, Vol. 17, No. 6, 15.03.2011, p. 1440-1451.

Research output: Contribution to journalArticle

Dong, G, Chanudet, E, Zeng, N, Appert, A, Chen, YW, Au, WY, Hamoudi, RA, Watkins, AJ, Ye, H, Liu, H, Gao, Z, Chuang, SS, Srivastava, G & Du, MQ 2011, 'A20, ABIN-1/2, and CARD11 mutations and their prognostic value in gastrointestinal diffuse large B-cell lymphoma', Clinical Cancer Research, vol. 17, no. 6, pp. 1440-1451. https://doi.org/10.1158/1078-0432.CCR-10-1859
Dong, Gehong ; Chanudet, Estelle ; Zeng, Naiyan ; Appert, Alex ; Chen, Yun Wen ; Au, Wing Yan ; Hamoudi, Rifat A. ; Watkins, A. James ; Ye, Hongtao ; Liu, Hongxiang ; Gao, Zifen ; Chuang, Shih Sung ; Srivastava, Gopesh ; Du, Ming Qing. / A20, ABIN-1/2, and CARD11 mutations and their prognostic value in gastrointestinal diffuse large B-cell lymphoma. In: Clinical Cancer Research. 2011 ; Vol. 17, No. 6. pp. 1440-1451.
@article{005d42c36a774d25bbcb46a415edc60f,
title = "A20, ABIN-1/2, and CARD11 mutations and their prognostic value in gastrointestinal diffuse large B-cell lymphoma",
abstract = "Purpose: Diffuse large B-cell lymphoma (DLBCL) is a heterogeneous group of aggressive lymphomas with the activated B-cell-like subtype characterized by constitutive NF-kB activation. Activating mutations of CARD11 and inactivating mutations of A20 are frequent events in DLBCL. However, the full extent of genetic alterations in the NF-κB pathway regulators and their potential prognostic value in DLBCL remain to be investigated. We investigated the genetic abnormalities of CARD11, A20, and ABIN-1/2/3 (the A20 binding inhibitor of NF-κB) and their clinicopathologic correlation in gastrointestinal DLBCL. Experimental Design: The somatic mutation and copy number changes of CARD11, A20, and ABIN-1/ 2/3 were investigated in 71 gastrointestinal DLBCLs by PCR/sequencing, and interphase FISH/array comparative genomic hybridization, respectively. The mutations identified were functionally characterized by NF-κB reporter assays and immunoprecipitation experiments. Results: Recurrent somatic mutations were found in CARD11 (10{\%}), A20 (17{\%}), ABIN-1 (4{\%}), and ABIN-2 (3{\%}), but not in ABIN-3. In comparison with the wild-type, all CARD11 mutants were potent NF-κB activators in vitro. On the basis of the destructive nature of the observed mutations, and the findings by reporter assays and immunoprecipitation studies, most if not all of the somatic mutations that were seen in A20, ABIN-1, and ABIN-2 could impair their normal functions. Among these genetic abnormalities, A20 somatic mutation was significantly associated with both poor overall survival and event-free survival. Conclusions: We show further evidence of NF-kB pathway genetic abnormalities in DLBCL, which are potentially valuable in the prognosis and design of future therapeutic strategies.",
author = "Gehong Dong and Estelle Chanudet and Naiyan Zeng and Alex Appert and Chen, {Yun Wen} and Au, {Wing Yan} and Hamoudi, {Rifat A.} and Watkins, {A. James} and Hongtao Ye and Hongxiang Liu and Zifen Gao and Chuang, {Shih Sung} and Gopesh Srivastava and Du, {Ming Qing}",
year = "2011",
month = "3",
day = "15",
doi = "10.1158/1078-0432.CCR-10-1859",
language = "English",
volume = "17",
pages = "1440--1451",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "6",

}

TY - JOUR

T1 - A20, ABIN-1/2, and CARD11 mutations and their prognostic value in gastrointestinal diffuse large B-cell lymphoma

AU - Dong, Gehong

AU - Chanudet, Estelle

AU - Zeng, Naiyan

AU - Appert, Alex

AU - Chen, Yun Wen

AU - Au, Wing Yan

AU - Hamoudi, Rifat A.

AU - Watkins, A. James

AU - Ye, Hongtao

AU - Liu, Hongxiang

AU - Gao, Zifen

AU - Chuang, Shih Sung

AU - Srivastava, Gopesh

AU - Du, Ming Qing

PY - 2011/3/15

Y1 - 2011/3/15

N2 - Purpose: Diffuse large B-cell lymphoma (DLBCL) is a heterogeneous group of aggressive lymphomas with the activated B-cell-like subtype characterized by constitutive NF-kB activation. Activating mutations of CARD11 and inactivating mutations of A20 are frequent events in DLBCL. However, the full extent of genetic alterations in the NF-κB pathway regulators and their potential prognostic value in DLBCL remain to be investigated. We investigated the genetic abnormalities of CARD11, A20, and ABIN-1/2/3 (the A20 binding inhibitor of NF-κB) and their clinicopathologic correlation in gastrointestinal DLBCL. Experimental Design: The somatic mutation and copy number changes of CARD11, A20, and ABIN-1/ 2/3 were investigated in 71 gastrointestinal DLBCLs by PCR/sequencing, and interphase FISH/array comparative genomic hybridization, respectively. The mutations identified were functionally characterized by NF-κB reporter assays and immunoprecipitation experiments. Results: Recurrent somatic mutations were found in CARD11 (10%), A20 (17%), ABIN-1 (4%), and ABIN-2 (3%), but not in ABIN-3. In comparison with the wild-type, all CARD11 mutants were potent NF-κB activators in vitro. On the basis of the destructive nature of the observed mutations, and the findings by reporter assays and immunoprecipitation studies, most if not all of the somatic mutations that were seen in A20, ABIN-1, and ABIN-2 could impair their normal functions. Among these genetic abnormalities, A20 somatic mutation was significantly associated with both poor overall survival and event-free survival. Conclusions: We show further evidence of NF-kB pathway genetic abnormalities in DLBCL, which are potentially valuable in the prognosis and design of future therapeutic strategies.

AB - Purpose: Diffuse large B-cell lymphoma (DLBCL) is a heterogeneous group of aggressive lymphomas with the activated B-cell-like subtype characterized by constitutive NF-kB activation. Activating mutations of CARD11 and inactivating mutations of A20 are frequent events in DLBCL. However, the full extent of genetic alterations in the NF-κB pathway regulators and their potential prognostic value in DLBCL remain to be investigated. We investigated the genetic abnormalities of CARD11, A20, and ABIN-1/2/3 (the A20 binding inhibitor of NF-κB) and their clinicopathologic correlation in gastrointestinal DLBCL. Experimental Design: The somatic mutation and copy number changes of CARD11, A20, and ABIN-1/ 2/3 were investigated in 71 gastrointestinal DLBCLs by PCR/sequencing, and interphase FISH/array comparative genomic hybridization, respectively. The mutations identified were functionally characterized by NF-κB reporter assays and immunoprecipitation experiments. Results: Recurrent somatic mutations were found in CARD11 (10%), A20 (17%), ABIN-1 (4%), and ABIN-2 (3%), but not in ABIN-3. In comparison with the wild-type, all CARD11 mutants were potent NF-κB activators in vitro. On the basis of the destructive nature of the observed mutations, and the findings by reporter assays and immunoprecipitation studies, most if not all of the somatic mutations that were seen in A20, ABIN-1, and ABIN-2 could impair their normal functions. Among these genetic abnormalities, A20 somatic mutation was significantly associated with both poor overall survival and event-free survival. Conclusions: We show further evidence of NF-kB pathway genetic abnormalities in DLBCL, which are potentially valuable in the prognosis and design of future therapeutic strategies.

UR - http://www.scopus.com/inward/record.url?scp=79952730520&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79952730520&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-10-1859

DO - 10.1158/1078-0432.CCR-10-1859

M3 - Article

C2 - 21266526

AN - SCOPUS:79952730520

VL - 17

SP - 1440

EP - 1451

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 6

ER -